NPPA Cuts Prices of 543 Cancer Drugs: 73% Reduced, MRP Cap of 30% Trade Margin Effective from 9 November
How much it matters for each exam
1At a glance
The National Pharmaceutical Pricing Authority (NPPA) has revised the Maximum Retail Prices (MRP) for 543 cancer drug brands/packs. 73% of these (397 drugs) have seen price reductions, with 217 slashed by over 50%. This follows a government order capping the trade margin for 137 anti-cancer drugs at 30% of MRP. The new prices come into effect from 9 November 2026.
Massive Price Cuts
NPPA has reduced prices for 73% of 543 cancer drugs, with over 200 seeing cuts greater than 50%.
Margin Regulation
Prices revised under a government order capping trade margins at 30% of MRP for 137 anti-cancer drugs.
Patented Drugs Unchanged
Prices of 146 drugs, including expensive patented ones like Keytruda, remain unchanged, exposing policy gaps.
2Facts to remember
Tap a card to see the answer. Try to recall it first.
3Detailed analysis
Context / Background
This regulatory action stems from longstanding public and judicial concern over exorbitant cancer drug prices in India. The Supreme Court, in September 2026, termed high cancer drug prices a 'massacre' and questioned the government on the wide gap between procurement cost and MRP. The NPPA operates under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, and regulates drug prices under the Drugs (Prices Control) Order (DPCO).
Core Analysis & Implications
The price revision demonstrates the impact of the Trade Margin Rationalization (TMR) policy, which aims to curb profiteering in the supply chain. The most drastic reduction is seen in Thiotepa 100mg injection (Samtepa), falling from Rs 80,071.86 to Rs 7,150.33. However, the policy's limitations are stark: patented drugs (e.g., Keytruda, Ribociclib) remain unaffected due to patent protections and complex supply chains. The policy also excludes drugs given free under patient assistance programs, missing an opportunity for broader price rationalization.
Future Outlook / Way Forward
The immediate challenge is ensuring the availability of reduced-price drugs and preventing companies from stopping supply. Long-term solutions require addressing policy flaws in TMR, such as the high permissible margin (up to 42.8%) on price-to-stockist for expensive drugs. Strengthening NPPA's data capabilities on supply chain pricing and exploring mechanisms like compulsory licensing or price negotiations for patented drugs are critical steps forward, as highlighted by the Supreme Court's intervention.
4Background GK
Textbook concepts you need to understand this news
- National Pharmaceutical Pricing Authority (NPPA)
- An independent body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, responsible for controlling and revising the prices of scheduled and non-scheduled drugs in India under the Drugs (Prices Control) Order (DPCO).
- Drugs (Prices Control) Order (DPCO)
- An order issued by the Government of India under the Essential Commodities Act, 1955, to regulate the prices of essential and life-saving medicines. The National List of Essential Medicines (NLEM) forms the basis for drugs under price control.
- Trade Margin Rationalization (TMR)
- A policy mechanism to cap the trade margin (the difference between the price to the retailer/stockist and the Maximum Retail Price) to prevent excessive profiteering in the pharmaceutical supply chain.
5How exams will ask this
- Data: 543 cancer drugs revised, 397 (73%) prices reduced, effective 9 Nov 2026.
- Nodal Body: National Pharmaceutical Pricing Authority (NPPA) under Dept. of Pharmaceuticals.
- Policy: Trade Margin Rationalization (TMR) policy capping margin at 30% of MRP.
Don't make this mistake!
They may ask about the percentage of drugs with reduced prices (73%) versus the number of drugs with price cuts greater than 50% (217). They may also swap 'patented drugs' with 'generic drugs' when discussing unchanged prices, or confuse DPCO with TMR.
Write these in mains answers
Affordable Healthcare, Drug Price Regulation, Supply Chain Transparency, Patents vs. Public Health
6Practice questions
Pick an answer, then read the explanation.
- Q1Hard
Consider the following statements regarding the recent revision of cancer drug prices:
- 1.The National Pharmaceutical Pricing Authority revised prices for 543 cancer drug brands/packs.
- 2.Prices of all patented cancer drugs, including Keytruda, were significantly reduced in this revision.
- 3.The revised prices are a result of a government order capping the trade margin for anti-cancer drugs at 30% of the Maximum Retail Price.
Which of the statements given above is/are correct?
Explanation: Statement 1 is correct as the article states NPPA revised prices for 543 drug brands/packs. Statement 2 is incorrect; the article specifically mentions that prices of patented drugs like Keytruda remained unchanged. Statement 3 is correct as the revision followed a government order capping trade margins at 30% of MRP.
- Q2Medium
According to the news, from what date are the newly revised prices of cancer drugs set to become effective?
Explanation: The article explicitly states that the new prices will come into effect from 9 November 2026. The other dates are distractors not mentioned in the content.
- Q3Medium
What is the primary objective behind the government's order to cap trade margins for anti-cancer drugs, as reflected in the recent price revision?
Explanation: The core objective of capping trade margins at 30% of MRP is to prevent excessive profiteering in the supply chain, thereby making essential cancer drugs more affordable for patients. This is evident from the Supreme Court's concern over the high cost of treatment and the article's focus on patient relief.
7All sources
Original29 October 2026 · Read story
Related stories
Stories from the last 30 days on the same topic, state or exams
India's IIP Grows 6.7% in September 2026, Led by 11.2% Surge in Electricity and 7.6% in Manufacturing
India's industrial output grew by 6.7% in September 2026 (Year-on-Year), indicating continued economic momentum. The growth was primarily driven by the Electricity & Gas Supply sector (11.2%) and Manufacturing (7.6%), while Mining & Quarrying contracted by 6.2%.
Full form of IIP: Index of Industrial Production
PMEGP's ₹1,000 Crore Subsidy Supports 11,333 Micro Enterprises, Generating Over 1.02 Lakh Jobs
The Prime Minister’s Employment Generation Programme (PMEGP) is a flagship credit-linked subsidy scheme aimed at creating self-employment through micro-enterprises in the non-farm sector. The recent release of ₹1,000 crore in Margin Money subsidy will support 11,333 new enterprises, facilitating bank credit of ₹3,260 crore and generating over 1.02 lakh sustainable jobs, with a strong focus on rural areas, SC/ST/OBC beneficiaries, and women entrepreneurs.
Full form of PMEGP: Prime Minister’s Employment Generation Programme
Container Manufacturing Promotion Scheme (CMPS): ₹10,000 Cr outlay to boost domestic capacity to 7.5 lakh TEUs by 2039-40
The Union Cabinet has approved the Container Manufacturing Promotion Scheme (CMPS) with a total outlay of ₹10,000 crore until 2039-40 to create a globally competitive container manufacturing ecosystem in India. The scheme aims to reduce import dependence, strengthen supply chains, and increase domestic manufacturing capacity tenfold to 7.5 lakh Twenty-foot Equivalent Units (TEUs).
Full form of CMPS: Container Manufacturing Promotion Scheme
Dearness Allowance Hiked to 63% for Central Govt Employees and Pensioners, Effective July 2026
The Union Government has increased Dearness Allowance (DA) for central government employees and Dearness Relief (DR) for pensioners by 3 percentage points to 63% of basic pay/pension. This revision, effective retrospectively from 1 July 2026, involves an annual financial implication of over Rs. 10,000 crore and benefits over 1.17 crore individuals.
New DA/DR Rate: 63% of basic pay/pension
2 sourcesKerala Infrastructure Investment Fund Board (KIIFB) faces winding up amid debate on off-budget borrowings, FRBM constraints
An expert panel in Kerala has recommended winding up the Kerala Infrastructure Investment Fund Board (KIIFB), an off-budget borrowing SPV, and absorbing its functions into the state government. This highlights the critical debate on state-level extra-budgetary resources (OBBs), fiscal discipline under the FRBM Act, and the trade-off between public investment and debt sustainability.
Full form of KIIFB: Kerala Infrastructure Investment Fund Board
PMAY-U 2.0 Interest Subsidy: ₹1.8 Lakh Subsidy on Home Loans up to ₹25 Lakh for EWS, LIG, MIG Families
The Pradhan Mantri Awas Yojana - Urban 2.0 includes an interest subsidy scheme offering up to ₹1.80 lakh subsidy on home loans up to ₹25 lakh. It targets Economically Weaker Sections (EWS), Low Income Group (LIG), and Middle Income Group (MIG) families with annual incomes up to ₹9 lakh. The scheme aims to make home ownership affordable for urban poor and middle-class families.
Full form of PMAY-U: Pradhan Mantri Awas Yojana - Urban
